Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years

Journal of the National Cancer Institute

Volumn 93, Issue 6, 2001, Pages 456-462

  Stewart, Helen J ^c   Prescott, Robin J ^a   Forrest, A Patrick M ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MASTECTOMY; MEDICAL INFORMATION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; UNITED KINGDOM;

EID: 0035925617     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.6.456     Document Type: Article

References (8)

1. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial
2. Randomised comparison of 5 years adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group
3. Clinical trial methodology
4. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial
5. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
6. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
7. Tamoxifen for early breast cancer: An overview of randomised trials
8. Tamoxifen therapy for breast cancer and endometrial cancer risk